Hormozd Bozorgchami, MD
Neurology · The Woodlands, TXNPI 1174770382
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,500 of the $13,790 with a category attached, or 83.4%. 17 manufacturers reported payments, led by MIVI Neuroscience, Inc. at 50.0% of the total. Reporting peaked in 2023 at $7,552 and has fallen 97.2% since, to $213 in 2025.
Across 51 payments — averaging $270.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MIVI Neuroscience, Inc.$7K
- Medical Device Business Services, Inc.$5K
- Stryker$674
- Medtronic$424
- Qapel Medical Inc$331
- Rapid Medical Ltd$213
- plus $648 from 11 others
Across 534 payments — averaging $1095.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$349K
- Medical Device Business Services, Inc.$125K
- E.r. Squibb & Sons, L.L.C.$105K
- Janssen Research & Development, LLC$6K
What the payments were for
- Consulting fees$11,50083%
- Food & beverage$2,19316%
- Education$971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MIVI Neuroscience, Inc. | 1 | $6,900 |
| Medical Device Business Services, Inc. | 3 | $4,600 |
| Stryker | 10 | $674 |
| Medtronic(2 entities) | 6 | $424 |
| Qapel Medical Inc | 3 | $331 |
| Rapid Medical Ltd | 2 | $213 |
| Imperative Care, Inc | 7 | $168 |
| Balt USA, LLC | 1 | $122 |
| Novo Nordisk | 3 | $97 |
| Johnson & Johnson | 4 | $74 |
| AbbVie | 3 | $53 |
| Genentech USA, Inc. | 3 | $47 |
| Abbott | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Penumbra, Inc. | 1 | $16 |
| Curonix LLC | 1 | $14 |
| Asahi Intecc USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBOTRAP II Revascularization Device$4,600
- TREVO$461
- TARGET$316
- TIGERTRIEVER 17 REVASCULARIZATION DEVICE$213
- COMANECI 17$213
- SURPASS EVOLVE$196
- Axium$151
- Ballast 088 Long Sheath$122
- Pipeline$109
- Solitaire$107
How this compares
$13,790 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 18 | $233 |
Paid to pharmacies, not to this prescriber.
Other neurology in The Woodlands
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.